Back to Top

The Vortex Biosciences mission is to be the innovation leader in CTC capture technology delivering diagnostic tests that improve therapeutic decisions and save lives.

We are in the midst of a paradigm shift in how cancer can be diagnosed and treated. The combination of targeted therapies and precise diagnostics is allowing for the era of personalized medicine to emerge. The capture and enrichment of circulating tumor cells is going to be a critical element of targeted companion diagnostics. We believe our next generation CTC capture system will allow the full diagnostic potential of CTCs to finally be realized.

Management & Board

François Martelet, MD

Chairman of the Board

François Martelet, Chief Executive Officer, joined NetScientific in 2015.

He brings over 20 years of biopharma experience and a proven track record of shaping and developing businesses to deliver returns. He has broad experience in both large and small companies, deep knowledge of commercialisation and has proven managerial capabilities.

Previously, François served as senior advisor to the CEO and Interim SVP at Stallergenes SA where he was responsible for international commercial strategies. During this period, sales revenues grew by 20+% and various new products were launched, including Oralair®, into ex-US markets. Before this, he was CEO at Topotarget A/S, a publicly traded European biotech company specialised in oncology therapeutics which he successfully transformed from a research based organisation into a late-stage clinical development company ready for a European exit.

Prior to this, François served as CEO of Avax Technologies Inc., a US biotech company specialised in therapeutic oncology vaccines. He has also held senior level commercial positions at Merck & Co, Inc. (VP & Global Franchise Head-Oncology), Novartis Pharma (SVP & Head of Central & Eastern Europe, Middle East and Africa), Schering-Plough and Eli Lilly.

François gained a Doctorate in Medicine and a Master’s Degree in Business from Dijon University, and holds a Degree in Legal Medicine from R. Descartes University School of Medicine, Paris. He is also a graduate of the Advanced General Management Program at INSEAD.

François Martelet’s awards include the Pasteur Institute medal (1989) and the Knight of the French National Order Merit (2011).

Dino Di Carlo, PhD

Board Member

Dino Di Carlo is Professor in the Department of Bioengineering at the University of California, Los Angeles (UCLA) where he directs the Microfluidic Biotechnology Laboratory. He is also a co-director of the Life Photonics Laboratory, a member of the California NanoSystems Institute (CNSI), and a member of the Jonsson Comprehensive Cancer Center – Cancer Nanotechnology Program Area. Dino received his B.S. in Bioengineering from the University of California, Berkeley in 2002 and received a Ph.D in Bioengineering from the University of California, Berkeley and San Francisco in 2006. He then conducted postdoctoral studies from 2006-2008 at the Center for Engineering in Medicine at Harvard Medical School and Massachusetts General Hospital. Professor Di Carlo has also received numerous academic honors including the U.S. National Science Foundation (NSF) Early CAREER Award, Office of Naval Research (ONR) Young Investigator Award, Packard Fellowship, Defense Advanced Research Projects Agency (DARPA) Young Faculty Award, National Institutes of Health (NIH) Director’s New Innovator Award, and Coulter Translational Research Award.

Professor Di Carlo has pioneered the use of fluid inertia for precision control of cells and particles and developed fundamental new methods of measuring cell physical properties and applying these measures to diagnose disease. Heis an inventor and continues to innovate around the core Vortex technology for filter-less and high-throughput collection of large cells from bodily fluids. As an engineer, inventor and entrepreneur, Professor Di Carlo founded, serves on the scientific advisory boards, or advises several early-stage companies including CytoVale, Ruubix, and Vortex Biosciences.

Dino Di Carlo, PhD

Board Member

Dino Di Carlo is Professor in the Department of Bioengineering at the University of California, Los Angeles (UCLA) where he directs the Microfluidic Biotechnology Laboratory. He is also a co-director of the Life Photonics Laboratory, a member of the California NanoSystems Institute (CNSI), and a member of the Jonsson Comprehensive Cancer Center – Cancer Nanotechnology Program Area. Dino received his B.S. in Bioengineering from the University of California, Berkeley in 2002 and received a Ph.D in Bioengineering from the University of California, Berkeley and San Francisco in 2006. He then conducted postdoctoral studies from 2006-2008 at the Center for Engineering in Medicine at Harvard Medical School and Massachusetts General Hospital. Professor Di Carlo has also received numerous academic honors including the U.S. National Science Foundation (NSF) Early CAREER Award, Office of Naval Research (ONR) Young Investigator Award, Packard Fellowship, Defense Advanced Research Projects Agency (DARPA) Young Faculty Award, National Institutes of Health (NIH) Director’s New Innovator Award, and Coulter Translational Research Award.

Professor Di Carlo has pioneered the use of fluid inertia for precision control of cells and particles and developed fundamental new methods of measuring cell physical properties and applying these measures to diagnose disease. Heis an inventor and continues to innovate around the core Vortex technology for filter-less and high-throughput collection of large cells from bodily fluids. As an engineer, inventor and entrepreneur, Professor Di Carlo founded, serves on the scientific advisory boards, or advises several early-stage companies including CytoVale, Ruubix, and Vortex Biosciences.

Jonathan Goldman, M.D

Scientific Advisor

Jonathan Goldman, M.D., is the Director of Clinical Trials in Thoracic Oncology and the Associate Director of Drug Development at UCLA Health. He completed his residency at UCSF and his fellowship in Hematology/Oncology at UCLA. His research focuses on cancer drug development with an emphasis on treatment for thoracic malignancies. In his role as the Director of Clinical Trials, he is working to develop novel anti-cancer drugs that have been identified in the lab and investigate their toxicity and efficacy with patients in the clinic. He is working on a diversity of projects on both targeted and immune therapies with Eli Lilly, Bristol Meyers Squibb, Astra Zeneca/MedImmune, and Roche/Genentech. Clinically, he cares for patients with many types of cancer, with a particular focus on treating lung cancer. He is always looking for new approaches to improve the efficiency of clinical trials. In collaboration with other departments, he has developed novel laboratory and radiographic techniques to aid in both patient stratification and patient monitoring. He received his degree from Harvard University and his M.D. from Stanford Medical School.

Massimo Cristofanilli, M.D

Scientific Advisor

Massimo Cristofanilli, MD, an expert in the translational research and treatment of patients with inflammatory breast cancer (IBC), is the Associate Director for Translational Research and Precision Medicine and Professor of Medicine in the Division of Hematology & Oncology at the Robert H Lurie Comprehensive Cancer Center, Northwestern University-Feinberg School of Medicine. Dr. Cristofanilli has led the development of novel diagnostic and prognostic markers in primary and metastatic breast cancer. His paper in the New England Journal of Medicine opened up the liquid biopsy field showing the prognostic importance of CTCs in breast cancer with the CellSearch system. In his research and academic role he is focused on advancing a patient-centered, biology driven model of cancer care; combining sophisticated tissue and blood-based molecular diagnostic technologies and innovative treatments. Prior to joining the Lurie Cancer Center, Dr. Cristofanilli was Director of the Breast Care Center and Deputy Director for Translational Research at the Sidney Kimmel Cancer Center at Thomas Jefferson University. He previously served as Chair of the Department of Medical Oncology at Fox Chase Cancer Center, and Executive Director of the Morgan Welch Inflammatory Breast Cancer Program and Clinic at the University of Texas MD Anderson Cancer Center.

Stanley Frankel, M.D

Scientific Advisor

Stanley Frankel, M.D., is an internationally recognized expert in the treatment of hematologic malignancies including ALL and lymphoma. He is currently the Corporate Vice President, Head of Immuno-oncology, Clinical Research and Development at Celgene. Through 2014 he served as Executive Director, Medical Sciences; Early Development, Oncology Therapeutic Area Head at Amgen. Among his primary responsibilities at Amgen were the clinical development of bispecific T cell engaging antibody constructs (BiTE®s) including blinatumomab. Prior experience includes roles as Vice President, Clinical Develoment at Micromet, Clinical Director and Clinical Science Leader at Hoffman-LaRoche; Executive Director for US External Scientific Affairs and Senior Director, Clinical Research at Merck. Dr. Frankel chaired the Zolinza Product Development Team and led the clinical efforts for the successful approval of Zolinza in 2006. From 2001-2004, he was Director, Medical Operations, at Genta, Inc working on Genasense. Prior to joining Genta, Dr. Frankel was Clinical Associate Professor of Medicine at the University of Maryland in Baltimore Greenebaum Cancer Center. He was previously on the faculty at Roswell Park Cancer Institute in Buffalo, NY and the Lombardi Cancer Center at Georgetown University. In addition to his contributions to the approval of Blincyto and Zolinza, Dr. Frankel worked as an academic investigator on the development of 11 other approved oncology drugs including Vesanoid and Trisenox for acute promyelocytic leukemia, Rituxan, Zevalin, Bexxar for CD20 expressing malignancies, Neulasta, Kepivance, Mylotarg, and Gleevec.

Elodie Sollier Christen, PhD

Chief Scientific Officer, Vice-President Research & Development

Elodie is Co-Founder, Chief Scientific Officer and Vice-President Research & Development for Vortex Biosciences, heading the initiatives for the commercialization of microfluidic devices for cancer research and diagnostics.

Elodie received a Physics Engineering Degree from Grenoble Institute of Technology and a PhD in Physics for Life Science from CEA LETI Minatec at Grenoble, France. Her PhD was followed by post-doctoral research in Bioengineering Department, University of California, Los Angeles, with Professor Dino Di Carlo. Her work resulted in the publication of articles in peer-reviewed journals, review papers, presentations in international conferences, and several patents including technologies licensed to Vortex Biosciences from UCLA.

Elodie’s expertise includes the development of new microfluidic devices for biological applications, focusing especially on blood sample preparation and analysis. She has been investigating different microfabrication approaches for transitioning from laboratory research to commercialization.

Ernest Schneider

Legal, Secretary & Board Member

Ernest Schneider is an English solicitor (attorney), patent & trade mark attorney and accredited mediator. He is the Commercial-Legal Director and Company Secretary of NetScientific plc and joined the Vortex Board in January 2016.

He was a partner with two large London law firms after which he established a successful international niche intellectual property firm. Ernest has negotiated and drafted numerous technology cross-license, joint venture and M&A agreements. He has masterminded, put in place and maintained a worldwide licensing programme with hundreds of combines patent, trademark and know-how license agreements. He has enforced, defended and challenged intellectual property rights around the world, conducting litigation, arbitration and mediation in most countries in Europe and in the USA, Canada, Hong Kong, Australia and New Zealand. Interwoven with his legal practice, Ernest has held executive and non-executive directorships and chairmanships in industry. He also has personal entrepreneurial experience, having set up and shut down a couple of business ventures of his own.

Ernest grew up in Lancaster, Florida and Luxembourg where he took his baccalauréat in sciences. He obtained his first degree in economics from Lancaster University Management School and then read law and postgraduate EU law at Leeds Business School. He is fluent in French, German and Lëtzebuergesch, has fluent but colloquial Hungarian and useful intermediate Spanish.

Deborah Neff

Board Member

Ms. Neff has served in a number of leadership positions in healthcare companies, including a 15-year career at Becton Dickinson & Co in executive management positions, making her ideally positioned to provide oversight to Vortex Biosciences. During her time at Becton Dickinson & Co, she was the Worldwide President of BD Biosciences with global P&L responsibilities. Under her leadership, the BD Biosciences grew to be a ~$700M business. Most recently, Deborah was the Chief Operating Officer of Complete Genomics Inc., where she led strategy development, established and delivered financial and operational milestones, and was responsible for operations, commercial and product development. Prior to that she was the President and Chief Executive Officer at both Predicant Biosciences Inc, and at Pathwork Diagnostics Inc., where she led the raising of capital, hiring of the executive team, development of an FDA cleared product, and achieved multi-million dollar annual sales. She was a member of the Board of Directors at Advanced Medical Optics Inc. and ForteBio Corporation Inc. prior to their being acquired, and is currently a member of the Board of Directors at Bio-Rad Laboratories.

Robert F. Englert

CEO & Board Member

Robert Englert is a Medical Device and Life Sciences executive with 25 years of global experience in IVD, Point of Care and digital health. Previously Bob was CEO and Founder of Biomedtrics Inc., a diabetes data management company where he raised funding and commercialized a mobile medical data device. Prior to that he was COO of Pelikan Technologies, a Point of Care glucose testing company. Earlier in his career Bob held multiple senior roles at Abbott Laboratories, including Business Unit Manager for Thyroid, Metabolic and Cardiovascular Diseases, Technical Support Director and Director of Operations. Bob has worked and lived in the U.S., Europe and Asia. In his various career roles, he has been responsible for the R&D, engineering, manufacturing and launch of numerous products across a spectrum of technologies including IVD immunoassays, Point of Care and digital health wireless devices. Bob received a Bachelor of Science Degree in Biology from the University of Illinois Urbana-Champaign.

Ian Postlethwaite

Board Member

Ian Postlethwaite, Chief Financial Officer, joined NetScientific in June 2016.
He brings over 14 years of biopharma experience and a proven track record of driving revenue growth and funding development programs. He has broad experience in both private and public companies; from start-ups to multi-nationals.

He was previously an Executive Director on the board of Allergy Therapeutics Plc. He joined Allergy in April 2002 as Finance Director whilst it was private company, initially performing a financial turnaround and then listing it two years later in 2004 on the AIM of the London Stock Exchange. Revenue increased from £12 to c.£49m over his tenure and he raised £107m through equity issues and €40m through debt finance to fund over 15 clinical studies.

Prior to this he worked for Ellerman Investments (1997-2002), a UK private equity house, undertaking the roles of Chief Executive Officer with AFS, which was one of the largest independent finance houses in the UK, raising over £400m in debt finance, and Finance Director with a number of successful start-up technology companies. Previously he held senior finance positions with Ericsson and Philips Electronics.

He is also a non-executive director and Deputy Chairman of Shoreham Port. He is a Fellow of the Chartered Association of Certified Accountants and has a BSc (Hons) in Geological Sciences from Aston University.

François Martelet, MD

Chairman of the Board

Robert F. Englert

CEO & Board Member

Deborah Neff

Board Member

Dino Di Carlo, PhD

Board Member

Elodie Sollier Christen, PhD

CSO

Ernest Schneider

Legal, Secretary & Board Member

Ian Postlethwaite

Board Member

Investors

Vortex Biosciences Inc, is a core subsidiary of NetScientific plc, a transatlantic biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at http://www.netscientific.net

 

Careers

Vortex Biosciences, Inc. is looking for dynamic individuals with expertise in cell and molecular biology, microfluidics, and commercialization of medical devices.

Openings may be available in other areas as the company expands. So, if you are interested in an entrepreneurial role with opportunity for growth, if you are passionate about new technologies for improving overall health, if you want to be a part of unlocking the challenges of early cancer detection, we encourage you to contact us.

For more information or to apply, fill out the form provided or email us at careers@vortexbiosciences.com.

SEND
 
Attach Resume/CV